Maravai Lifesciences Holdings - Class A (MRVI) closed at $8.02 on November 9, 2026, up 6.6% from the previous close, on volume of 1,990,098 shares (30-day average 2,422,121).
Data as of November 9, 2026.
9-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Calendar Call Spread | 18-Dec-26 : 19-Mar-27 5 C | 200 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Maravai (MRVI) lifts 2026 outlook after Q3 revenue rose 10.1% and Adjusted EBITDA turned positive
Market Chameleon (Thu, 5-Nov 4:39 AM ET)
Maravai LifeSciences Reports Third Quarter 2026 Financial Results
Business Wire (Wed, 4-Nov 4:01 PM ET)
Maravai LifeSciences Announces November 2026 Investor Conference Schedule
Business Wire (Thu, 29-Oct 4:01 PM ET)
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
Business Wire (Wed, 14-Oct 4:01 PM ET)
Business Wire (Tue, 29-Sep 4:01 PM ET)
Market Chameleon (Fri, 8-May 6:32 AM ET)
Maravai LifeSciences Guides for 2026 Growth Despite 2025 Revenue Drop and Restructuring Moves
Market Chameleon (Thu, 26-Feb 5:40 AM ET)
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
Maravai Lifesciences Holdings - Class A trades on the NASDAQ stock market under the symbol MRVI.
As of November 9, 2026, MRVI stock price climbed to $8.02 with 1,990,098 million shares trading.
MRVI has a beta of 0.40, meaning it tends to be less sensitive to market movements. MRVI has a correlation of 0.00 to the broad based SPY ETF.
MRVI has a market cap of $1.19 billion. This is considered a Small Cap stock.
Last quarter Maravai Lifesciences Holdings - Class A reported $46 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.03.
In the last 3 years, MRVI traded as high as $11.56 and as low as $1.67.
The top ETF exchange traded funds that MRVI belongs to (by Net Assets): VTI, IWM, VXF, IWN, FYC.
MRVI has outperformed the market in the last year with a price return of +177.5% while the SPY ETF gained +13.4%. MRVI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.3% and +9.6%, respectively, while the SPY returned -1.8% and -1.0%, respectively.
MRVI support price is $7.13 and resistance is $7.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRVI shares will trade within this expected range on the day.
